Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Authors
Type
Published Article
Journal
Journal of Clinical Oncology
1527-7755
Publisher
American Society of Clinical Oncology
Publication Date
Volume
28
Issue
30
Pages
4594–4600
Identifiers
DOI: 10.1200/JCO.2010.28.8415
PMID: 20855825
Source
Medline

Abstract

Statistics

Seen <100 times